Abstract
Background/Aim
Biliary tract cancers (BTCs) have poor prognoses, with limited curative options beyond surgical resection. Adjuvant S-1 chemotherapy has shown survival benefits in Japanese patients undergoing resection for BTC. However, prognostic factors influencing survival in these patients remain uncertain. In this study, we aimed to investigate the efficacy of preoperative nutritional status using the Global Leadership Initiative on Malnutrition (GLIM) criteria as a prognostic factor in patients receiving adjuvant S-1 chemotherapy for BTC.
Patients and Methods
In this retrospective study, excluding intrahepatic cholangiocarcinoma, we evaluated 58 patients who underwent curative surgery for BTC at Kobe University from 2013 to 2022, followed by adjuvant S-1 chemotherapy. Nutritional status was classified by GLIM criteria into normal/moderate and severe malnutrition groups. Overall (OS) and recurrence-free (RFS) survival were analyzed using Kaplan-Meier and Cox proportional hazards models.
Results
Of the 58 patients, 3.4% had no malnutrition, 72.5% had moderate malnutrition, and 24.1% had severe malnutrition. Patients with severe malnutrition had significantly worse 5-year OS (24.7% vs. 52.5%, p=0.0014) and RFS (34.3% vs. 52.0%, p=0.0066). Severe malnutrition was an independent prognostic factor for poorer OS (hazard ratio=3.40, 95% confidence interval=1.46-7.94; p=0.0047) and RFS (hazard ratio=2.48, 95% confidence interval=1.07-5.76; p=0.035). No significant difference in S-1 completion rates was observed.
Conclusion
Severe malnutrition, as defined by GLIM criteria, is a poor prognostic factor in patients with BTCs undergoing adjuvant S-1 chemotherapy.
Keywords: Biliary tract cancer, GLIM criteria, adjuvant S-1 chemotherapy
Introduction
Biliary tract cancer (BTC) includes intrahepatic cholangio-carcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, gallbladder cancer, and ampullary cancer (1). In Japanese cancer staging, extrahepatic cancer, gallbladder cancer and ampullary cancer are classified as biliary tract cancers, while intrahepatic cholangiocarcinoma is often classified in accordance with hepatocellular carcinoma (2). Surgical resection is the only potentially curative treatment; however, the 5-year survival rate post-resection remains below 40% (3). Recently, the Japan Clinical Oncology Group 1202 (JCOG1202) study (UMIN000011688), a randomized phase III trial conducted on patients with BTC, demonstrated the superiority of adjuvant S-1 chemotherapy over surgery alone for overall survival (OS) [hazard ratio (HR)=0.694, p=0.008] (4). Adjuvant S-1 chemotherapy may become a standard treatment in patients undergoing resection of BTC.
In recent years, the association between nutritional status and prognosis in gastrointestinal cancers has gained significant attention (5,6). Sarcopenia has emerged as a significant prognostic indicator in patients undergoing chemotherapy for colorectal and pancreatic cancer (6,7). In 2018, the Global Leadership Initiative on Malnutrition (GLIM) introduced internationally recognized diagnostic criteria for malnutrition (8), which are now being used to predict outcomes of various diseases (9,10). Prognostic factors for BTC include positive resection margins (11,12), infiltration into other organs (13-15), lymph node metastasis (12), vascular invasion (12,15), lymphatic invasion (16), perineural invasion (12,15), preoperative cholangitis (17), type of histology such as poorly differentiated adenocarcinoma and mucinous carcinoma (11), and preoperative carbohydrate antigen 19-9 (CA19-9) level (18). Severe malnutrition diagnosed by GLIM criteria has been identified as a poor prognostic factor for postoperative outcomes, including in extrahepatic cholangiocarcinoma (19).
Based on the JCOG1202 study, the number of patients receiving adjuvant S-1 chemotherapy following surgery for BTC is expected to rise. However, prognostic factors in patients with resected BTC undergoing S-1 adjuvant chemotherapy remain unclear, although an association between chemotherapy outcomes and preoperative malnutrition diagnosed by GLIM criteria has been reported in other cancer types (7,20).
In this study, we aimed to investigate the efficacy of preoperative nutritional status, as diagnosed by the GLIM criteria, as a prognostic factor in patients receiving adjuvant S-1 chemotherapy for BTC.
Patients and Methods
Patients. This retrospective study included 276 patients who underwent radical surgery for BTC, excluding intrahepatic cholangiocarcinoma, at the Department of Hepato-Biliary-Pancreatic Surgery, Kobe University between January 2013 and December 2022. Patients with pathological tumor stage Tis (carcinoma in situ) or T1 (early-stage tumors), distant metastasis, macroscopic residual cancer after resection (R2 resection), and multiple simultaneous primary cancer were excluded. A total of 58 patients who received adjuvant chemotherapy were included in the final analysis. We collected clinical and laboratory data from medical records. The study was approved by the Ethics Committee of Kobe University and conducted following the Helsinki Declaration (approval ID number: B240153). Informed consent was obtained from all patients through an opt-out approach.
Surgical treatment and follow-up. Hemi-hepatectomy or tri-sectionectomy extending to the caudate lobe with extrahepatic bile duct resection was performed for perihilar cholangiocarcinoma and gallbladder cancer. Pancreatoduodenectomy was performed for distal cholangiocarcinoma, gallbladder cancer, and ampullary cancer. A liver bed resection was performed for gallbladder cancer. Extrahepatic bile duct resection was carried out only for patients with middle bile duct cancer and poor performance status. Since 2013, when the JCOG1202 trial began, S-1 adjuvant chemotherapy has been administered at our Institution to patients with tumors classified as T2 or higher or those with lymph node metastasis.
Following the JCOG1202 protocol, patients received an oral dose of S-1 twice daily for 4 weeks, followed by a 2-week rest period. Three dosage levels of S-1 were used based on body surface area: <1.25 m2: 40 mg; 1.25 m2 to <1.50 m2: 50 mg; and ≥1.50 m2: 60 mg, twice daily. Patients with creatinine clearance levels of 50-60 ml/min received a 10 mg reduction of each dose. Treatment was continued for up to four cycles or 24 weeks (4). Patients were followed up for 5 years with serum tumor maker levels and enhanced computed tomography or magnetic resonance imaging at least every 3-6 months after surgery.
Definition of malnutrition diagnosis by the GLIM criteria in this study. For preoperative malnutrition diagnosis, the GLIM criteria recommend combining at least one phenotypic criterion (nonvolitional weight loss, low body mass index, or reduced muscle mass) and one etiological criterion (reduced food intake/assimilation or disease burden/inflammatory status) (8). In this study, malnutrition diagnosis was based on the phenotypic criterion, as patients with cancer already meet the etiological criterion of disease burden. Patients diagnosed with malnutrition were classified as having moderate or severe malnutrition based on the phenotypic criterion. The body mass index and L3- Skeletal Muscle Index (SMI) cutoff values used to distinguish moderate from severe malnutrition were based on previous reports (19).
Statistical analysis. Continuous and categorical variables are expressed as medians, ranges, and ratios. Continuous variables were compared using the Kruskal-Wallis test, while categorical variables were compared using the chi-squared or Fisher’s exact test, as appropriate. OS was defined as the time from surgery to death from any cause or the most recent follow-up. Recurrence-free survival (RFS) was defined as the time from surgery, BTC relapse, death, or the most recent follow-up. Univariable and multivariable Cox proportional hazards regression models were used to estimate HRs and 95% confidence intervals (CIs) for RFS and OS. Multivariate analysis was performed for factors with p<0.05 in the univariate analysis. OS and RFS were calculated using the Kaplan-Meier method, and differences between curves were assessed using the log-rank test. A two-tailed p<0.05 was considered statistically significant. All statistical analyses were performed using the JMP statistical program (version 16; SAS Institute Inc., Cary, NC, USA).
Results
Between 2000 and 2022, 483 patients underwent curative resection for BTC. Patients with tumor invasion depths of Tis to T1, distant metastasis, macroscopic residual cancer after resection, and double cancer were excluded from this group. A total of 58 patients who received postoperative adjuvant S-1 chemotherapy were included in the study (Figure 1). According to the GLIM criteria, two patients (3.4%) had no malnutrition, 42 patients (72.5%) were classified as having moderate malnutrition, and 14 patients (24.1%) were classified as having severe malnutrition. Due to the small number of patients without malnutrition, the normal and moderate malnutrition groups were combined for comparison with the severe malnutrition group. Severe malnutrition was significantly more common in males; however, no statistically significant differences were found in other factors, including age, preoperative cholangitis, CA19-9 level, tumor location, histology, tumor invasion depth, lymph node metastasis, lymphatic invasion, vascular invasion, perineural invasion, or microscopic residual cancer (Table I).
Figure 1.
The flow diagram of this study on patients with biliary tract cancer (BTC).
Table I. Baseline characteristics of patients undergoing adjuvant S-1 chemotherapy for biliary tract cancer according to nutritional status classified by the Global Leadership Initiative on Malnutrition (GLIM) criteria.
CA19-9: carbohydrate antigen 19-9; pap: papillary adenocarcinoma; UICC: Union for International Cancer Control, classification seventh edition; Well: tubular adenocarcinoma, well-differentiated. Statistically significant p-values are shown in bold.
Figure 2 shows the Kaplan–Meier analysis for OS and RFS based on preoperative nutritional status diagnosed using the GLIM criteria. In the normal and moderate malnutrition group, the 1-, 3-, and 5-year OS rates were 100%, 70.9% and 52.5%, respectively. In the severe malnutrition group, the corresponding rates were 85.7%, 37.0% and 24.7%, respectively. OS rates were significantly worse in the severe malnutrition group compared to the normal and moderate groups (p=0.0014). For RFS, the 1-, 3-, and 5-year rates in the normal and moderate malnutrition groups were 90.9%, 57.2%, and 52.0%, respectively. In the severe malnutrition group, the corresponding rates were 71.4%, 34.3% and 34.3%, respectively. RFS rates were significantly lower in the severe malnutrition group compared to the normal and moderate groups (p=0.0066).
Figure 2.
Kaplan-Meier curve of overall (OS) (A) and recurrence-free (RFS) (B) survival according to the status by the Global Leadership Initiative on Malnutrition criteria after resection of biliary tract cancer. The patients of the severe malnutrition group had poorer OS (p=0.0014) and RFS (p=0.0066) than those of the normal and moderate malnutrition groups, with 1-, 3- and 5-year OS rates of 100% vs. 85.7%, 70.9% vs. 37.0%, and 52.5% vs. 24.7%; and RFS rates of 90.9% vs. 71.4%, 57.2% vs. 34.3% and 52.0% vs. 34.3%, respectively.
Table II shows the risk factors associated with OS. In the univariate analysis, a high CA19-9 level, lymph node metastasis, microscopic residual cancer, and severe malnutrition were identified as prognostic factors for poorer OS. In the multivariate analysis, microscopic residual cancer (HR=2.97, 95% CI=1.25-7.04; p=0.014) and severe malnutrition (HR=3.40, 95% CI=1.46-7.94; p=0.0047) were independent prognostic factors.
Table II. Univariate and multivariate analysis for overall survival of patients undergoing adjuvant S-1 chemotherapy for biliary tract cancer.
CA19-9: Carbohydrate antigen 19-9; GLIM: Global Leadership Initiative on Malnutrition; HR: hazard ratio; LN: lymph node; pap: papillary adenocarcinoma; UICC: Union for International Cancer Control classification seventh edition; well: tubular adenocarcinoma, well-differentiated. Statistically significant p-values are shown in bold.
The factors associated with RFS are shown in Table III. Lymph node metastasis, lymphatic invasion, perineural invasion, microscopic residual cancer, and severe malnutrition were identified as prognostic factors in the univariate analysis. In the multivariate analysis, severe malnutrition (HR=2.48, 95% CI=1.07-5.76; p=0.035) was the only independent prognostic factor.
Table III. Univariate and multivariate analysis for recurrence-free survival of patients undergoing adjuvant S-1 chemotherapy for biliary tract cancer.
CA19-9: Carbohydrate antigen 19-9; GLIM: Global Leadership Initiative on Malnutrition; HR: hazard ratio; LN: lymph node; pap: papillary adenocarcinoma; UICC: Union for International Cancer Control classification seventh edition; well: tubular adenocarcinoma, well-differentiated. Statistically significant p-values are shown in bold.
Discussion
BTCs have a poor prognosis, with surgical resection recognized as the only potentially curative treatment. The JCOG study recently demonstrated that adjuvant S-1 chemotherapy prolongs overall survival in Japanese patients with resected BTCs. Postoperative adjuvant S-1 chemotherapy is now the standard of care in Japan and is expected to become the standard in Asia. However, prognostic factors in these patients remain unclear. The GLIM criteria, proposed in 2018, are used to diagnose nutritional status, and malnutrition diagnosed using the GLIM criteria has been reported as a prognostic factor in various cancer types (21,22). To our knowledge, this study is the first to demonstrate the prognostic impact of preoperative nutritional status diagnosed using the GLIM criteria in patients after BTC resection who received postoperative adjuvant S-1 chemotherapy.
Microscopic residual cancer and preoperative severe malnutrition, as diagnosed by the GLIM criteria, were independent prognostic factors in patients undergoing adjuvant S-1 chemotherapy. Severe malnutrition emerged as the only significant prognostic factor, suggesting that assessing preoperative nutritional status using the GLIM criteria is valuable for prognostic stratification.
Adjuvant S-1 chemotherapy can cause adverse events due to its toxicity, including gastrointestinal symptoms (nausea, vomiting, and diarrhea), neutropenia, hand−foot syndrome, and general fatigue (4,23,24). In this study, adverse events were evaluated using the Common Terminology Criteria for Adverse Events version 5.0 (25). Grade 3 or higher adverse events included anemia, thrombocytopenia, neutropenia, diarrhea, drug rash, and fatigue (Table IV). The normal and moderate malnutrition groups had 10 cases (25.6%) of adverse events, while the severe malnutrition group had three (25%), with no significant difference between the groups (p=0.96). The proportion of S-1 treatment completion was 75% in the normal and moderate malnutrition groups and 78.6% in the severe malnutrition group (p=0.53). Since S-1 treatment completion rates were similar between groups, the preoperative nutritional status may be a potential prognostic factor.
Table IV. Adverse events (>grade 3) experienced by patients undergoing adjuvant S-1 chemotherapy for biliary tract cancer according to nutritional status as defined by Global Leadership Initiative on Malnutrition (GLIM) criteria.
As adjuvant S-1 chemotherapy following surgery for BTCs becomes more widespread, evaluating preoperative nutritional status and addressing malnutrition is crucial. Reports emphasize the importance of preoperative nutritional interventions, recommending routine high-protein oral nutritional supplements, immuno-nutrition, carbohydrate loading, and structured nutritional prehabilitation to optimize surgical outcomes and promote recovery (26,27). These interventions aim to boost metabolic reserves, reduce complication risks, and improve overall survival, particularly in vulnerable patients undergoing cancer treatment (26,27). Furthermore, future research should examine whether these interventions improve nutritional status as determined by the GLIM criteria and whether these improvements correlate with patient prognosis.
Malnutrition has been reported as a risk factor for poor compliance with adjuvant S-1 chemotherapy following gastric cancer surgery (20); however, we found no difference in the completion rate of adjuvant S-1 chemotherapy between the normal/moderate malnutrition group and the severe malnutrition group.
The relationship between chronic inflammation caused by tumors and malnutrition has been well documented. Tumor-related inflammatory mediators, such as tumor necrosis factor α, interleukin-6, and interleukin-1β, suppress appetite, delay gastric emptying, and promote skeletal muscle catabolism, contributing to the multiple mechanisms that cause malnutrition (28). This suggests that malnutrition diagnosed using the GLIM criteria may reflect the degree of cachexia (29). Furthermore, cachexia has been reported to reduce chemotherapy efficacy. Therefore, patients diagnosed with severe malnutrition according to the GLIM criteria may experience reduced effectiveness of adjuvant S-1 chemotherapy.
Study limitations. Firstly, this retrospective study was conducted at a single institution with a small sample size. Secondly, due to the long study period, there was inconsistency in perioperative management, surgical techniques, and chemotherapy regimens. Thirdly, there were limitations in defining muscle mass loss. One of the phenotypic criteria in the GLIM criteria is reduced muscle mass; however, various methods exist for its assessment. In this study, the SMI was measured at the L3 level using computed tomographic scans, and cutoff values from previous studies were used (19). Generally, patients with BTC have reduced muscle mass compared to the general adult population, and further research is needed to establish disease-specific SMI values.
Conclusion
In cases where adjuvant S-1 chemotherapy is administered after surgery for BTC, severe preoperative malnutrition as diagnosed by the GLIM criteria has been identified as a poor prognostic factor. Evaluating preoperative nutritional status with the GLIM criteria is valuable for prognostic stratification for patients receiving postoperative adjuvant S-1 chemotherapy for advanced BTC.
Conflicts of Interest
The Authors declare no conflicts of interest for this article.
Authors’ Contributions
Hiroaki Yanagimoto and Ryunosuke Konaka designed the study. Masayuki Akita, Takuya Mizumoto, Toshihiko Yoshida, Shinichi Sou, Jun Ishida, Yoshihide Nanno, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Sadaki Asari, Masahiro Kido, Hirochika Toyama and Takumi Fukumoto contributed to data collection, interpretation of data, and critical revision of manuscript. Ryunosuke Konaka drafted the manuscript. All Authors have read and agreed to the published version of the manuscript.
Acknowledgements
The Authors thank all patients and health care providers who contributed to this study.
Funding
No funding was received for this study.
References
- 1.Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428–444. doi: 10.1016/S0140-6736(21)00153-7. [DOI] [PubMed] [Google Scholar]
- 2.Miyazaki M, Ohtsuka M, Miyakawa S, Nagino M, Yamamoto M, Kokudo N, Sano K, Endo I, Unno M, Chijiiwa K, Horiguchi A, Kinoshita H, Oka M, Kubota K, Sugiyama M, Uemoto S, Shimada M, Suzuki Y, Inui K, Tazuma S, Furuse J, Yanagisawa A, Nakanuma Y, Kijima H, Takada T. Classification of biliary tract cancers established by the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery: 3rd English edition. J Hepatobiliary Pancreat Sci. 2015;22(3):181–196. doi: 10.1002/jhbp.211. [DOI] [PubMed] [Google Scholar]
- 3.Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, Ebata T, Konishi M, Sano K, Shimada K, Shimizu H, Higuchi R, Wakai T, Isayama H, Okusaka T, Tsuyuguchi T, Hirooka Y, Furuse J, Maguchi H, Suzuki K, Yamazaki H, Kijima H, Yanagisawa A, Yoshida M, Yokoyama Y, Mizuno T, Endo I. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. J Hepatobiliary Pancreat Sci. 2021;28(1):26–54. doi: 10.1002/jhbp.870. [DOI] [PubMed] [Google Scholar]
- 4.Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J, Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG‑HBPOG) Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): A multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401(10372):195–203. doi: 10.1016/S0140-6736(22)02038-4. [DOI] [PubMed] [Google Scholar]
- 5.Okumura S, Kaido T, Hamaguchi Y, Fujimoto Y, Masui T, Mizumoto M, Hammad A, Mori A, Takaori K, Uemoto S. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery. 2015;157(6):1088–1098. doi: 10.1016/j.surg.2015.02.002. [DOI] [PubMed] [Google Scholar]
- 6.Vergara-Fernandez O, Trejo-Avila M, Salgado-Nesme N. Sarcopenia in patients with colorectal cancer: A comprehensive review. World J Clin Cases. 2020;8(7):1188–1202. doi: 10.12998/wjcc.v8.i7.1188. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Kurita Y, Kobayashi N, Tokuhisa M, Goto A, Kubota K, Endo I, Nakajima A, Ichikawa Y. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology. 2019;19(1):127–135. doi: 10.1016/j.pan.2018.11.001. [DOI] [PubMed] [Google Scholar]
- 8.Jensen GL, Cederholm T, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, de Baptista GA, Barazzoni R, Blaauw R, Coats AJS, Crivelli A, Evans DC, Gramlich L, Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE, Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren M, Siltharm S, Singer P, Tappenden KA, Velasco N, Waitzberg DL, Yamwong P, Yu J, Compher C, Van Gossum A. GLIM criteria for the diagnosis of malnutrition: a consensus report from the Global Clinical Nutrition Community. J Parenter Enteral Nutr. 2019;43(1):32–40. doi: 10.1002/jpen.1440. [DOI] [PubMed] [Google Scholar]
- 9.de van der Schueren MAE, Keller H, GLIM Consortium, Cederholm T, Barazzoni R, Compher C, Correia MITD, Gonzalez MC, Jager-Wittenaar H, Pirlich M, Steiber A, Waitzberg D, Jensen GL. Global Leadership Initiative on Malnutrition (GLIM): Guidance on validation of the operational criteria for the diagnosis of protein-energy malnutrition in adults. Clin Nutr. 2020;39(9):2872–2880. doi: 10.1016/j.clnu.2019.12.022. [DOI] [PubMed] [Google Scholar]
- 10.Mori N, Maeda K, Fujimoto Y, Nonogaki T, Ishida Y, Ohta R, Shimizu A, Ueshima J, Nagano A, Fukushima R. Prognostic implications of the global leadership initiative on malnutrition criteria as a routine assessment modality for malnutrition in hospitalized patients at a university hospital. Clin Nutr. 2023;42(2):166–172. doi: 10.1016/j.clnu.2022.12.008. [DOI] [PubMed] [Google Scholar]
- 11.Wellner UF, Shen Y, Keck T, Jin W, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today. 2017;47(3):271–279. doi: 10.1007/s00595-016-1362-0. [DOI] [PubMed] [Google Scholar]
- 12.Klempnauer J, Ridder GJ, Werner M, Weimann A, Pichlmayr R. What constitutes long-term survival after surgery for hilar cholangiocarcinoma. Cancer. 1997;79(1):26–34. [PubMed] [Google Scholar]
- 13.Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases. Ann Surg Oncol. 2007;14(3):1212–1219. doi: 10.1245/s10434-006-9260-0. [DOI] [PubMed] [Google Scholar]
- 14.Ito H, Ito K, D'Angelica M, Gonen M, Klimstra D, Allen P, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg. 2011;254(2):320–325. doi: 10.1097/SLA.0b013e31822238d8. [DOI] [PubMed] [Google Scholar]
- 15.Chan C, Herrera MF, de la Garza L, Quintanilla-Martinez L, Vargas-Vorackova F, Richaud-Patín Y, Llorente L, Uscanga L, Robles-Diaz G, Leon E. Clinical behavior and prognostic factors of periampullary adenocarcinoma. Ann Surg. 1995;222(5):632–637. doi: 10.1097/00000658-199511000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Shibata K, Uchida H, Iwaki K, Kai S, Ohta M, Kitano S. Lymphatic invasion: an important prognostic factor for stages T1b–T3 gallbladder cancer and an indication for additional radical resection of incidental gallbladder cancer. World J Surg. 2009;33(5):1035–1041. doi: 10.1007/s00268-009-9950-4. [DOI] [PubMed] [Google Scholar]
- 17.Akita M, Ajiki T, Matsumoto T, Shinozaki K, Goto T, Asari S, Toyama H, Kido M, Fukumoto T, Ku Y. Preoperative cholangitis affects survival outcome in patients with extrahepatic bile duct cancer. J Gastrointest Surg. 2017;21(6):983–989. doi: 10.1007/s11605-017-3388-z. [DOI] [PubMed] [Google Scholar]
- 18.Yamamoto R, Sugiura T, Ashida R, Ohgi K, Yamada M, Otsuka S, Uesaka K. Prognostic value of carbohydrate antigen 19-9 and the surgical margin in extrahepatic cholangiocarcinoma. Ann Gastroenterol Surg. 2021;6(2):307–315. doi: 10.1002/ags3.12525. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Okazoe Y, Yanagimoto H, Tsugawa D, Akita M, Asakura R, Omiya S, Urade T, Nanno Y, Fukushima K, Gon H, Komatsu S, Kuramitsu K, Goto T, Asari S, Toyama H, Kido M, Ajiki T, Fukumoto T. Prognostic impact of malnutrition diagnosed by the GLIM criteria for resected extrahepatic cholangiocarcinoma. Anticancer Res. 2023;43(5):2299–2308. doi: 10.21873/anticanres.16394. [DOI] [PubMed] [Google Scholar]
- 20.Matsui R, Inaki N, Tsuji T. Effect of malnutrition as defined by the Global Leadership Initiative on Malnutrition criteria on compliance of adjuvant chemotherapy and relapse-free survival for advanced gastric cancer. Nutrition. 2023;109:111958. doi: 10.1016/j.nut.2022.111958. [DOI] [PubMed] [Google Scholar]
- 21.Matsui R, Inaki N, Tsuji T. Impact of GLIM defined malnutrition on long term prognosis in patients with gastric cancer after gastrectomy. Anticancer Res. 2022;42(9):4611–4618. doi: 10.21873/anticanres.15965. [DOI] [PubMed] [Google Scholar]
- 22.Zhang X, Tang M, Zhang Q, Zhang KP, Guo ZQ, Xu HX, Yuan KT, Yu M, Braga M, Cederholm T, Li W, Barazzoni R, Shi HP. The GLIM criteria as an effective tool for nutrition assessment and survival prediction in older adult cancer patients. Clin Nutr. 2021;40(3):1224–1232. doi: 10.1016/j.clnu.2020.08.004. [DOI] [PubMed] [Google Scholar]
- 23.Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–1820. doi: 10.1056/NEJMoa072252. [DOI] [PubMed] [Google Scholar]
- 24.Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(1):74–84. doi: 10.1016/S1470-2045(20)30534-9. [DOI] [PubMed] [Google Scholar]
- 25.Common Terminology Criteria for Adverse Events (CTCAE) Version 5. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. [Last accessed on March 12, 2025]
- 26.Williams DGA, Wischmeyer PE. Nutrition Status Optimization for Improved Perioperative Outcomes. Curr Anesthesiol Rep. 2022;12(1):59–64. doi: 10.1007/s40140-021-00504-y. [DOI] [Google Scholar]
- 27.West MA, Wischmeyer PE, Grocott MPW. Prehabilitation and nutritional support to improve perioperative outcomes. Curr Anesthesiol Rep. 2017;7(4):340–349. doi: 10.1007/s40140-017-0245-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Stumpf F, Keller B, Gressies C, Schuetz P. Inflammation and nutrition: friend or foe. Nutrients. 2023;15(5):1159. doi: 10.3390/nu15051159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Ni J, Zhang L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Manag Res. 2020;12:5597–5605. doi: 10.2147/CMAR.S261585. [DOI] [PMC free article] [PubMed] [Google Scholar]